Multi-omic study to unmask genes involved in prostate cancer development in a multi-case family

Lucia Chica-Redecillas; Sergio Cuenca-Lopez; Eduardo Andres-Leon; Laura Carmen Terron-Camero; Blanca Cano-Gutierrez; Jose Manuel Cozar; Jose Antonio Lorente; Fernando Vazquez-Alonso; Luis Javier Martinez-Gonzalez; Maria Jesus Alvarez-Cubero

doi:10.1002/cac2.12501

PDF

Cancer Communications ›› 2024, Vol. 44 ›› Issue (3) : 443-447. DOI: 10.1002/cac2.12501

LETTER TO THE EDITOR

Multi-omic study to unmask genes involved in prostate cancer development in a multi-case family

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Lucia Chica-Redecillas, Sergio Cuenca-Lopez, Eduardo Andres-Leon, Laura Carmen Terron-Camero, Blanca Cano-Gutierrez, Jose Manuel Cozar, Jose Antonio Lorente, Fernando Vazquez-Alonso, Luis Javier Martinez-Gonzalez, Maria Jesus Alvarez-Cubero. Multi-omic study to unmask genes involved in prostate cancer development in a multi-case family. Cancer Communications, 2024, 44(3): 443‒447 https://doi.org/10.1002/cac2.12501

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Nicolosi P, Ledet E, Yang S, Michalski S, Freschi B, O'Leary E, et al. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. JAMA Oncol. 2019;5(4):523-528.

[2]	Dillon KM, Bekele RT, Sztupinszki Z, Hanlon T, Rafiei S, Szallasi Z, et al. PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer. NPJ Precis Oncol. 2022;6(1):49.

[3]	Stewart DR, Best AF, Williams GM, Harney LA, Carr AG, Harris AK, et al. Neoplasm Risk Among Individuals With a Pathogenic Germline Variant in DICER1. J Clin Oncol. 2019;37(8):668-676.

[4]	Jung H, Lee KS, Choi JK. Comprehensive characterisation of intronic mis-splicing mutations in human cancers. Oncogene. 2021;40(7):1347-1361.

[5]	Bugter JM, Fenderico N, Maurice MM. Mutations and mechanisms of WNT pathway tumour suppressors in cancer. Nat Rev Cancer. 2021;21(1):5-21.

[6]	Caruso S, Calderaro J, Letouzé E, Nault JC, Couchy G, Boulai A, et al. Germline and somatic DICER1 mutations in familial and sporadic liver tumors. J Hepatol. 2017;66(4):734-742.

[7]	Brogna S, Wen J. Nonsense-mediated mRNA decay (NMD) mechanisms. Nat Struct Mol Biol. 2009;16(2):107-113.

[8]	Murillo-Garzón V, Kypta R. WNT signalling in prostate cancer. Nat Rev Urol. 2017;14(11):683-696.

[9]	Katoh M. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β-catenin signaling activation (Review). Int J Mol Med. 2018;42(2):713-725.

[10]	Wang J, Zhang K, Wang J, Wu X, Liu X, Li B, et al. Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma. Oncotarget. 2015;6(22):18905-18920.